Cargando…

mRNA BNT162b Vaccine Elicited Higher Antibody and CD4(+) T-Cell Responses than Patients with Mild COVID-19

We compared the development and persistence of antibody and T-cell responses elicited by the mRNA BNT162b2 vaccine or SARS-CoV-2 infection. We analysed 37 post-COVID-19 patients (15 with pneumonia and 22 with mild symptoms) and 20 vaccinated subjects. Anti-Spike IgG and neutralising antibodies were...

Descripción completa

Detalles Bibliográficos
Autores principales: Zavaglio, Federica, Cassaniti, Irene, Sammartino, Josè Camilla, Tonello, Stelvio, Sainaghi, Pier Paolo, Novelli, Viola, Meloni, Federica, Lilleri, Daniele, Baldanti, Fausto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228401/
https://www.ncbi.nlm.nih.gov/pubmed/35744768
http://dx.doi.org/10.3390/microorganisms10061250
_version_ 1784734459030929408
author Zavaglio, Federica
Cassaniti, Irene
Sammartino, Josè Camilla
Tonello, Stelvio
Sainaghi, Pier Paolo
Novelli, Viola
Meloni, Federica
Lilleri, Daniele
Baldanti, Fausto
author_facet Zavaglio, Federica
Cassaniti, Irene
Sammartino, Josè Camilla
Tonello, Stelvio
Sainaghi, Pier Paolo
Novelli, Viola
Meloni, Federica
Lilleri, Daniele
Baldanti, Fausto
author_sort Zavaglio, Federica
collection PubMed
description We compared the development and persistence of antibody and T-cell responses elicited by the mRNA BNT162b2 vaccine or SARS-CoV-2 infection. We analysed 37 post-COVID-19 patients (15 with pneumonia and 22 with mild symptoms) and 20 vaccinated subjects. Anti-Spike IgG and neutralising antibodies were higher in vaccinated subjects and in patients with pneumonia than in patients with mild COVID-19, and persisted at higher levels in patients with pneumonia while declining in vaccinated subjects. However, the booster dose restored the initial antibody levels. The proliferative CD4(+) T-cell response was similar in vaccinated subjects and patients with pneumonia, but was lower in mild COVID-19 patients and persisted in both vaccinated subjects and post-COVID patients. Instead, the proliferative CD8(+) T-cell response was lower in vaccinated subjects than in patients with pneumonia, decreased six months after vaccination, and was not restored after the booster dose. The cytokine profile was mainly T(H)1 in both vaccinated subjects and post-COVID-19 patients. The mRNA BNT162b2 vaccine elicited higher levels of antibody and CD4(+) T-cell responses than those observed in mild COVID-19 patients. While the antibody response declined after six months and required a booster dose to be restored at the initial levels, the proliferative CD4(+) T-cell response persisted over time.
format Online
Article
Text
id pubmed-9228401
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92284012022-06-25 mRNA BNT162b Vaccine Elicited Higher Antibody and CD4(+) T-Cell Responses than Patients with Mild COVID-19 Zavaglio, Federica Cassaniti, Irene Sammartino, Josè Camilla Tonello, Stelvio Sainaghi, Pier Paolo Novelli, Viola Meloni, Federica Lilleri, Daniele Baldanti, Fausto Microorganisms Article We compared the development and persistence of antibody and T-cell responses elicited by the mRNA BNT162b2 vaccine or SARS-CoV-2 infection. We analysed 37 post-COVID-19 patients (15 with pneumonia and 22 with mild symptoms) and 20 vaccinated subjects. Anti-Spike IgG and neutralising antibodies were higher in vaccinated subjects and in patients with pneumonia than in patients with mild COVID-19, and persisted at higher levels in patients with pneumonia while declining in vaccinated subjects. However, the booster dose restored the initial antibody levels. The proliferative CD4(+) T-cell response was similar in vaccinated subjects and patients with pneumonia, but was lower in mild COVID-19 patients and persisted in both vaccinated subjects and post-COVID patients. Instead, the proliferative CD8(+) T-cell response was lower in vaccinated subjects than in patients with pneumonia, decreased six months after vaccination, and was not restored after the booster dose. The cytokine profile was mainly T(H)1 in both vaccinated subjects and post-COVID-19 patients. The mRNA BNT162b2 vaccine elicited higher levels of antibody and CD4(+) T-cell responses than those observed in mild COVID-19 patients. While the antibody response declined after six months and required a booster dose to be restored at the initial levels, the proliferative CD4(+) T-cell response persisted over time. MDPI 2022-06-18 /pmc/articles/PMC9228401/ /pubmed/35744768 http://dx.doi.org/10.3390/microorganisms10061250 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zavaglio, Federica
Cassaniti, Irene
Sammartino, Josè Camilla
Tonello, Stelvio
Sainaghi, Pier Paolo
Novelli, Viola
Meloni, Federica
Lilleri, Daniele
Baldanti, Fausto
mRNA BNT162b Vaccine Elicited Higher Antibody and CD4(+) T-Cell Responses than Patients with Mild COVID-19
title mRNA BNT162b Vaccine Elicited Higher Antibody and CD4(+) T-Cell Responses than Patients with Mild COVID-19
title_full mRNA BNT162b Vaccine Elicited Higher Antibody and CD4(+) T-Cell Responses than Patients with Mild COVID-19
title_fullStr mRNA BNT162b Vaccine Elicited Higher Antibody and CD4(+) T-Cell Responses than Patients with Mild COVID-19
title_full_unstemmed mRNA BNT162b Vaccine Elicited Higher Antibody and CD4(+) T-Cell Responses than Patients with Mild COVID-19
title_short mRNA BNT162b Vaccine Elicited Higher Antibody and CD4(+) T-Cell Responses than Patients with Mild COVID-19
title_sort mrna bnt162b vaccine elicited higher antibody and cd4(+) t-cell responses than patients with mild covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228401/
https://www.ncbi.nlm.nih.gov/pubmed/35744768
http://dx.doi.org/10.3390/microorganisms10061250
work_keys_str_mv AT zavagliofederica mrnabnt162bvaccineelicitedhigherantibodyandcd4tcellresponsesthanpatientswithmildcovid19
AT cassanitiirene mrnabnt162bvaccineelicitedhigherantibodyandcd4tcellresponsesthanpatientswithmildcovid19
AT sammartinojosecamilla mrnabnt162bvaccineelicitedhigherantibodyandcd4tcellresponsesthanpatientswithmildcovid19
AT tonellostelvio mrnabnt162bvaccineelicitedhigherantibodyandcd4tcellresponsesthanpatientswithmildcovid19
AT sainaghipierpaolo mrnabnt162bvaccineelicitedhigherantibodyandcd4tcellresponsesthanpatientswithmildcovid19
AT novelliviola mrnabnt162bvaccineelicitedhigherantibodyandcd4tcellresponsesthanpatientswithmildcovid19
AT melonifederica mrnabnt162bvaccineelicitedhigherantibodyandcd4tcellresponsesthanpatientswithmildcovid19
AT lilleridaniele mrnabnt162bvaccineelicitedhigherantibodyandcd4tcellresponsesthanpatientswithmildcovid19
AT baldantifausto mrnabnt162bvaccineelicitedhigherantibodyandcd4tcellresponsesthanpatientswithmildcovid19